Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From AC Immune SA

Blow For Sweden's BioArctic As AbbVie Exits Parkinson's Pact

Novartis and Roche may be committed to the target, but AbbVie has decided that its efforts in Parkinson's will not include a Phase II trial of its Swedish partner's alpha synuclein drug.

Deals Neurology

Minute Insight: First Live Images Of Alpha-Synuclein Raise Hope For Improved Neurological Diagnostics

Advancements in imaging technology may bring medtech and pharma closer together and lead to better drugs for neurological conditions.

Minute Insights Clinical Trials

Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders

Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.

Clinical Trials Business Strategies

Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances

Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.

Scrip Asks Coronavirus COVID-19
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Molecular Diversity
  • Other Names / Subsidiaries
    • AC Immune, Ltd.
UsernamePublicRestriction

Register